Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre.

摘要: Background & Aims This study aims to assess the cost-effectiveness of a routine universal antenatal hepatitis C virus (HCV) screening programme at London centre. Methods Ten years' retrospective and outcome data informed analysis using previously validated MONARCH model. The cost quality life outcomes associated with treatment newly identified cases were used generate estimates for programme. Results A total 35,355 women screened between 1st November 2003 March 2013; 136 (0.38%) found be HCV antibody positive. Of 78 (0.22%) viraemic cases, 44 (0.12%) diagnosed. In addition, three (6.8%) vertical transmissions in children diagnosed mothers. 16 mothers biopsied, all F0-F2 METAVIR disease stages, 50% had genotype 1. Postnatal pegylated interferon ribavirin was initiated 19 women, 14 (74%) achieving sustained virologic response. confirmation diagnoses estimated £240,641. translates £5469 per individual. incremental ratio this strategy £2400 QALY gained. Treatment newer direct-acting antiviral regimens would have projected £9139 gained, well below £20,000-30,000/QALY gained willingness-to-pay threshold applied by policy advisory bodies. Conclusions demonstrates that an is feasible effective, considered acceptable.